Galapagos snags co-promotion rights on filgotinib — just before Gilead’s lock-up pact expires
Exactly two years after Gilead $GILD stepped in with $725 million in cash to buy into licensing rights for Galapagos’ $GLPG spotlight drug filgotinib, the Belgian biotech has decided to grab the European co-promotion rights it had left for itself in the deal. And market wags won’t overlook the fact that the original deal they worked out included a lockup and standstill agreement for Gilead to sit on its 13.27% stake — right up until that part of the pact expires in just 17 days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
